Abundance of studies explore pharmacotherapy for cataract

November 1, 2020
Cheryl Guttman Krader, BS, Pharm

Interest stems from the recognition that the number of people affected with cataracts is expected to increase in association with population aging while access to cataract surgery is limited in areas throughout the world.

A number of compounds have shown promising potential for preventing and reversing cataracts in preclinical studies and warrant further investigation as possible pharmacotherapy alternatives to surgical management, according to authors of an article that reviewed the effects of natural and synthetic agents on experimentally induced cataracts.1

Interest in pharmacotherapy for cataract stems from the recognition that the number of people affected with cataracts is expected to increase in association with population aging while access to cataract surgery is limited in areas throughout the world.

The authors of the article wrote, “With the projected increase in life expectancies, the number of people affected with cataract is predicted to increase worldwide. The prognosis of the disease is at best oblique in low-income nations that lack easy and affordable access to cataract surgery. Therefore, the potential therapeutic and economic benefits of pharmacological cataract treatments are immeasurable, ranging from a reduction in economic burden to better quality of life.”

The authors go on to suggest that plant-derived compounds or extracts are particularly attractive, especially in developing nations. They explain that compared with traditional medications, the costs of both development and patient use may be lower with the plant-derived agents given their accessibility.

Comprehensive content

The extensive 41-page review article includes 288 references. As background to the discussion of treatment strategies for cataracts, the authors describe lens anatomy, physiology, transparency, and antioxidant systems. They also provide an overview of the molecular mechanisms of cataract formation that include models based on protein aggregation and/or loss of protein solubility.

The summary of compounds identified by the researchers as having been investigated for anti-cataract activity includes plant-derived agents, herbal remedies, ketoacids/amino acids, and other agents with antioxidant and free radical scavenging activity. The compounds investigated also include pharmacological chaperons that bind α-crystallins in the lens to reverse protein aggregation and enhance protein solubility as well as agents that target glycation-specific mechanisms, phase separation, the transforming growth factor-β pathway, and matrix metalloproteinase.

The paper features two tables that summarize key features of studies relevant to pharmacotherapy for cataracts. One table focuses on the in vitro and ex vivo cataractogenesis studies and the other lists the in vivo studies of cataractogenesis. The latter studies were done almost entirely in murine models with just two experiments performed in rabbits and a single experiment in guinea pigs. The modes of application include subcutaneous injection, dietary modification, topical treatment, oral (including gavage/gastric intubation), and intraperitoneal or subcutaneous injection.

Future directions

Noting that lutein/zeaxanthin supplementation did not have a significant benefit for decreasing progression of senile cataract in the Age-Related Eye Disease Study 2 and that an extensive Cochrane review failed to find any anti-cataract benefit of antioxidant vitamin supplementation, the authors suggested that better drug delivery methods might allow for better efficacy.

Looking ahead, the researchers also suggested that a better understanding of the mechanisms of cataract development should be pursued as it could lead to the identification of new therapeutic targets for pharmacological strategies to prevent or reverse lens opacity.

Reference
  1. Heruye SH, Maffofou Nkenyi LN, et al. Current trends in the pharmacotherapy of cataracts. Pharmaceuticals (Basel). 2020;13(1):15.

Related Content:

Cataract Therapeutics | News